Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

607 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: hiraoka a. Aliment Pharmacol Ther. 2024 Jul;60(2):233-245. doi: 10.1111/apt.18037. Epub 2024 May 8. Aliment Pharmacol Ther. 2024. PMID: 38716823 Clinical Trial.
Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment.
Hiraoka A, Kumagi T, Hirooka M, Uehara T, Kurose K, Iuchi H, Hiasa Y, Matsuura B, Michitaka K, Kumano S, Tanaka H, Yamashita Y, Horiike N, Mochizuki T, Onji M. Hiraoka A, et al. World J Gastroenterol. 2006 Apr 7;12(13):2075-9. doi: 10.3748/wjg.v12.i13.2075. World J Gastroenterol. 2006. PMID: 16610060 Free PMC article.
Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications.
Hiraoka A, Horiike N, Yamashita Y, Koizumi Y, Doi K, Yamamoto Y, Hasebe A, Ichikawa S, Yano M, Miyamoto Y, Ninomiya T, Otomi Y, Kokame M, Iwamura T, Ishimaru Y, Sogabe I, Kashihara K, Nishiura S, Ootani H, Takamura K, Kawasaki H. Hiraoka A, et al. Hepatogastroenterology. 2008 Nov-Dec;55(88):2171-4. Hepatogastroenterology. 2008. PMID: 19260499
Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization.
Hiraoka A, Horiike N, Yamashita Y, Koizumi Y, Doi H, Yamamoto Y, Ichikawa S, Hasebe A, Yano M, Miyamoto Y, Ninomiya T, Ootani H, Takamura K, Kawasaki H, Otomi Y, Kogame M, Sogabe I, Ishimaru Y, Kashihara K, Miyagawa M, Hirooka M, Hiasa Y, Matsuura B, Michitaka K, Onji M. Hiraoka A, et al. Hepatogastroenterology. 2009 Jan-Feb;56(89):213-7. Hepatogastroenterology. 2009. PMID: 19453060
Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients.
Hiraoka A, Michitaka K, Horiike N, Hidaka S, Uehara T, Ichikawa S, Hasebe A, Miyamoto Y, Ninomiya T, Sogabe I, Ishimaru Y, Kawasaki H, Koizumi Y, Hirooka M, Yamashita Y, Abe M, Hiasa Y, Matsuura B, Onji M. Hiraoka A, et al. J Gastroenterol Hepatol. 2010 Feb;25(2):403-7. doi: 10.1111/j.1440-1746.2009.06037.x. Epub 2009 Nov 19. J Gastroenterol Hepatol. 2010. PMID: 19929922
607 results